Today: 22 January 2026
Subscribe
Browse Category

CSE:NOVO.B News 17 January 2026 - 19 January 2026

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

COPENHAGEN, Jan 19, 2026, 21:15 CET — Trading wrapped up for the day. Novo Nordisk shares slipped on Monday, giving back a portion of last week’s rally as investors weighed early demand data for the company’s new Wegovy weight-loss drug ahead of the trading week. The Copenhagen-listed B shares fell 2.8%, ending the day at 378.15 Danish crowns after moving…
19 January 2026
····
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Copenhagen, January 17, 2026, 21:05 CET — The market has closed. Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle. (Investing) This move…
17 January 2026
·····

Stock Market Today

  • Four Seasons Education (NYSE:FEDU) Shares Tumble 30% Amid Mixed Growth Signals
    January 22, 2026, 6:48 AM EST. Shares of Four Seasons Education (Cayman) Inc. (NYSE:FEDU) have plunged 30% in the past month, continuing a difficult 27% decline over the last year. Despite a seemingly attractive price-to-earnings (P/E) ratio of 13.5x, below the U.S. market average of roughly 20x, the company's uneven earnings growth raises concerns. After a striking 323% earnings per share increase last year, the firm showed no growth across the past three years, suggesting inconsistent performance. This lag behind the broader market's projected 16% expansion likely explains the low P/E and wary investor sentiment. The sharp stock drop reflects caution about the company's future growth prospects, signaling that its current valuation more so captures investor apprehension than undervaluation.
Go toTop